388 results about "Ginsenoside Rg1" patented technology

Personal care composition comprising from about 0.05% to about 5% of at least one aquaporin-stimulating compound selected from the group consisting of xanthine, caffeine; 2-amino-6-methyl-mercaptopurine; 1-methyl xanthine; 2-aminopurine; theophylline; theobromine; adenine; adenosine; kinetin; p-chlorophenoxyacetic acid; 2,4-dichlorophenoxyacetic acid; indole-3-butyric acid; indole-3-acetic acid methyl ester; beta-naphthoxyacetic acid; 2,3,5-triiodobenzoic acid; adenine hemisulfate; n-benzyl-9-(2-tetrahydropyranyl)adenine; 1,3-diphenylurea; 1-phenyl-3-(1,2,3-thiadiazol-5-yl)urea; zeatin; indole-3-acetic acid; 6-benzylaminopurine; alpha-napthaleneacetic acid; 6-2-furoylaminopurine; green tea extract; white tea extract; menthol; tea tree oil; ginsenoside-RB1; ginsenoside-RB3; ginsenoside-RC; ginsenoside-RD; ginsenoside-RE; ginsenoside-RG1; ginseng root extract; ginseng flower extract; pomegranate extract, extracts from Ajuga turkestanica; extracts from viola tricolor and combinations thereof; an additional ingredient selected from the group consisting of niacinamide, glycerin and mixtures thereof, and a dermatologically-acceptable carrier.

The invention discloses a dressing composition used for inhibiting scars and accelerating wound healing and application thereof. The dressing composition consists of chitosan, acidic polysaccharide and panax notoginseng saponins in a weight proportion of 100:10-50:10-100, wherein the chitosan is selected from chitosan, chitosan lactate, acetate and hydrochloride; the acidic polysaccharide is selected from sodium carboxymethyl chitosan, sodium hyaluronate, zinc hyaluronate, sodium alginate and sodium carboxymethyl cellulose; and the panax notoginseng saponins accounts for no less than 40.0 percent of the total weight of ginsenosides Rg1 and Rb1. The formulations of the dressing composition are xerogel powder, capsules, gel membranes, hydrogels and fiber coatings. The dressing composition is used for wounds, burns, scalds, crush injuries, skin ulcers, gastroenteric ulcers and no healing of the wounds, has the advantages of rapid hemostasis, exudate reduction, moisturizing, air permeability, bacteriostasis, inflammation diminishing, itch relieving, no adhesion, effective inhibition of scarring, remarkable reduction of wound healing time and no need of replacing dressings, so that thedressing composition basically meets requirements of perfect functional external dressings.

The invention relates to a composite of active ingredients of Chinese herb medicine used for preventing the damage of cerebral ischemia and relevant diseases, in particular to a preparation which is prepared by the active ingredients of the Chinese herb medicine; the preparation is prepared by the active ingredients of the Chinese herb medicine and the conventional preparation technique which is used by carriers permitted by pharmacy, and comprises the following components with the parts by weight: 2 to 10 parts of ginsenoside Rb, 2 to 10 parts of ginsenoside Rg1, 1 to 5 parts of ginsenoside Rd, 1 to 5 parts of ginsenoside Re, 2 to 10 parts of stilbene glycoside, 1 to 5 parts of ginkgolide and 1 to 5 parts of flavonoid mixture which consists of kaempferol and quercetin with the weight rate to be 1:1. The invention has the advantages that the defects that in the traditional compounded Chinese medicine, the composition is complex, the product quality is not controlled effectively and the curative effect is not stable are overcome, has clear ingredients, definite effect, stable quality and obvious control effect on ischemic stroke, sequela, cerebral arteriosclerosis and vascular dementia, can improve the functions of motor nerve, and learning and memory of the patients, has low toxicity and simple preparation method without obvious side effect and is suitable for industrial mass production.

The invention belongs to the medicine technical filed, in particular to a preparation method of monomeric compound ginsenoside Rg1, ginsenoside Rb1 and total arasaponin and the application in the medicine field thereof. The fresh medicinal material, the dried medicinal material and the medicinal material on the market of Panax notoginseng are taken as the raw materials; according to the polarity and the solubility property of a compound, separation and purification are carried out by adopting the solvent extraction method, the crystallization process and the chromatography and total arasaponin powder is prepared by combining the common drying means, such as decompression concentration drying, freeze drying, vacuum drying and the like; by carrying out one or more methods of recrystal, normal phase, opposite phase silica gel column chromatography, daiamid column chromatography and sephadex chromatography and the like on the powder, the ginsenoside Rg1 and the ginsenoside Rb1 monomers are prepared. The medicines which take the ginsenoside Rg1 and the ginsenoside Rb1 monomers or the total arasaponin as the active ingredients can be used for preventing and/or curing the senile dementia, the neurodegenerative diseases, the cerebrovascular disorder, various dysmnesia, the central lesion and other diseases.

The invention provides a radix notoginseng extract which contains 5-10% of notoginsenoside R1, 25-36% of ginsenoside Rg1, 2.5-5% of ginsenoside Re, 30-39% of ginsenoside Rb1, 5-10% of ginsenoside Rd and at least 2% of ginsenoside Rf, ginsenoside Rh1, ginsenoside Rc, ginsenoside Rb2 and ginsenoside Rg3, wherein the ginsenoside R1, the ginsenoside Rg1, the ginsenoside Re, the ginsenoside Rb1 and the ginsenoside Rd account for 75-95% of the total weight. The invention also provides a preparation method of the radix notoginseng extract. The radix notoginseng extract prepared by the method has little impurities, the purity of the component of total saponin is higher, and especially, the components of the ginsenoside Rf, the ginsenoside Rh1, the ginsenoside Rc, the ginsenoside Rb2, the ginsenoside Rg3 and the like with very low content are purified. The medicinal preparation prepared by the radix notoginseng extract has better curative effect and higher safety.

A technique for processing ginseng has the steps that gardenia is taken, cleaned and selected; the part of the gardenia which is damaged by worm and rotted is removed; the processed gardenia is ground into powder with 20-100 meshes and is added with 20-30 times of water to be soaked for 1-24 hours in a sealing way, and then gardenia honey mixing suspension is obtained by adding 30% of honey . Fresh ginseng pieces with the thicknesses of 1-3mm are soaked into 0.5 time of gardenia honey mixing suspension for 6-24 hours, stewed for 1-3 hours and taken out; and then the ginseng pieces are placed into a heating oven to be dried at the temperature of 40-50 DEG C until the color of the ginseng pieces burn and ginseng pieces are not sticky, finally, the obtained ginseng pieces are spread out to be dried. The processed ginseng products which are obtained by adopting the method is added with gardenoside having anti-inflammation and heat reducing ingredients, and the content of the active ingredients, which are ginsenosides Rg1, Re and Rb1 is changed, thus achieving the purpose of reducing characteristics of warmth and dryness. The new processed products not only have the efficacy of traditional ginseng, but also reduce the characteristics of warmth and dryness of ginseng; thus the newly processed products can well play the role of health care such as fatigue resistance, anti-aging and intelligence development, and the like, and have good stability and controllable quality, so as to be creative innovation for solving the problem of drug property of ginseng and have certain economic and social benefits.

The invention discloses a medicinal composition, which is mainly prepared from compound salvianolic acid B and ginsenoside Rg1 according to a certain weight part ratio. The medicinal composition has a protection effect on cardiac muscle in myocardial ischemia and reperfusion and can be used for treating cardiovascular diseases.

The present invention relates to Chinese medicine quality detecting technology, and is especially the quality detection method for compound preparation of red sage and notoginseng. HPLC-DAD process is adopted to measure the contents of protocatechuic aldehyde, salvianolic acid B, cryptotanshinone, neotanshinone IIA, arasaponin R1, ginsenoside Rg1 and ginsenoside Rb1 in compound red sage preparation simultaneously. The process is simple, precise, repeatable and reliable, and may be used in the quality control of compound red sage preparation.

The invention discloses a composition for treating cardiovascular diseases and a preparation method thereof. The composition comprises (by weight part) Radix Ginseng Rubra saponin 2-20, Ophiopogon japonicus saponin 0.2-3, and Ophiopogon japonicus flavone 0.02-3; wherein the Radix Ginseng Rubra saponin extract contains (by dry weight) ginsenoside Rg1 not less than 9.0%, ginsenoside Re not less than 3.0%, ginsenoside Rb1 not less than 12.0%, and Panax ginseng total saponins not less than 80%; the Ophiopogon japonicus saponin extract contains (by dry weight) ophiopogonin D not less than 6.0%, ophiopogonin D' not less than 6.0%, and Ophiopogon japonicus total saponins not less than 80%; and the Ophiopogon japonicus flavone extract contains (by dry weight) methylophiopogonone A and methylophiopogonone B in total not less than 80%. Animal experiments showed that the composition has good therapeutic action on myocardial ischemia and has better anti-shock effect.

The invention discloses an Rg2 group and an Rh1 group of red ginseng saponin and a preparation method as well as applications in preparing cosmetics preventing skin aging. Extracts which are extracted from ginseng roots, do not contain saponin, and contain saponin enzyme of ginseng and other water-soluble matters react with ginsenoside Re to obtain red ginseng mixed saponin Rg2 group consisting of red ginseng rare saponin 20(S)-Rg2, 20(R)-Rg2, Rg4 and Rg6, and the extracts react with ginsenoside Rg1 to obtain the red ginseng mixed saponin Rh1 group consisting of red ginseng rare saponin 20(S)-Rh1, 20(R)-Rh1, Rh4 and Rk3. Compared with a saponin Rg2 monomer and a saponin Rh1 monomer, the function of the Rg2 group and Rh1 group of red ginseng mixed saponin for promoting skin fibroblast collagen synthesis is improved obviously, the Rg2 group and Rh1 group of red ginseng mixed saponin are more safe to skin and human bodies, and have less side effects.

The invention relates to panax notoginseng saponins medicine combination and the application thereof, which are characterized in that the active ingredient is composed of panax notoginseng saponins which contains notoginsenoside R1, ginsenoside Rg1, ginsenoside Rb1, ginsenoside Re, ginsenoside Rd, ginsenoside Rb3 and ginsenoside Rb2; the combination with different contents and ingredients of saponins are prepared; the combinations have different treatment effects.

The invention discloses applications of glycosyltransferase and related materials thereof in the construction of engineering bacteria for producing ginsenoside Rb1 and Rg1. A glycosyltransferase genePn3-32 which can catalyze ginsenoside Rd to generate ginsenoside Rb1 can be successfully identified through a synthetic biological method; and the gene can simultaneously catalyze ginsenoside F1 to generate ginsenoside Rg1 and construct recombinant yeast producing the ginsenoside Rb1 and the ginsenoside Rg1. Through experiments, the constructed recombinant yeast producing the ginsenoside Rb1 and the ginsenoside Rg1 can simultaneously generate the ginsenoside Rb1 and the ginsenoside Rg1. Pn1-31, Pn-3-29, Pn3-31 and Pn3-32 glycosyltransferase genes in medicinal plant radix notoginseng are firstly utilized to continuously catalyze protopanaxadiol and protopanaxatriol to synthetize the ginsenoside Rb1, the ginsenoside Rg1 and corresponding intermediates, so that novel cases can be provided formicrobial strains to produce natural products.

The invention provides a medicinal composition, which comprises the following components: ginsenoside Rb1, ginsenoside Rg1, notoginsenoside R1, ginsenoside Rd, ginsenoside Re, ginsenoside Rf, ginsenoside Rc, ginsenoside Rh1, ginsenoside Rb2 and ginsenoside Rg3. The invention also provides a preparation method for the medicinal composition. The medicinal composition has definite components; compared with the total notoginsenoside in the prior art, the medicinal composition has stable quality and good controllability; and results of experiments of acute toxicity, undue toxicity, hemolysis and the like show that the medicinal composition has higher safety and wide clinical application prospect.

The invention relates to a detection method of compound danshen dripping pills, comprising the following contents of: observation of characters, discrimination of contents, inspection of contents, comparison of finger prints and assaying of contained components. The detection method provided by the invention comprises a discriminating method of the medicinal component panax notoginseng, the discriminating method adopts thin-layer chromatography, the reference materials adopt a panax notoginseng reference medicinal material, a ginsenoside Rg1 reference substance, a ginsenoside Re reference substance, a ginsenoside Rb1 reference substance and a panax notoginseng saponin R1 reference substance. The detection method provided by the invention also comprises a discriminating method and an assaying method of the medicinal component danshen, wherein the discriminating method adopts a sub-2 mu m liquid chromatography technology to perform chromatographic fingerprint discrimination, and adopts sodium danshensu as a reference material; and the assaying method adopts a sub-2 mu m liquid chromatography technology to perform assaying on the components such as danshensu, panax notoginseng saponin R1, ginsenoside Rg1 and ginsenoside Rb1 in the danshen.

The invention discloses a method for extracting and separating total saponins of panax ginseng from american ginseng. The method employs a series of high-efficiency extraction, separation and purification technical measures of alcohol-backflow extracting, water precipitating, purifying by a macroporous adsorption resin, decolorizing with an ion exchange resin, etc. The obtained total saponins of panax ginseng are white powder and comprise ginsenoside Rg1, ginsenoside Re, ginsenoside Rb1, ginsenoside Rc and ginsenoside Rd, wherein the total purity of ginsenoside Rg1, ginsenoside Re and ginsenoside Rb1 is more than 74.0%. The production process is simple and practical, has no pollution, and is suitable for large-scale production.

The present invention discloses a UPLC-MS quantitative method for the contents of twelve components in a traditional Chinese medicine composition preparation, specifically determination of the contents of calycosin-7-O-beta-D-glucoside (1), isoquercitrin (2), narirutin (3), hesperidin (4), ginsenoside Re (5), ginsenoside Rg1(6), periplocoside (7), ginsenoside Rf (8), ginsenoside Rb1 (9), astragaloside (10), ginsenoside Rd (11) and periplocin H1 (12) in the traditional Chinese medicine composition, and belongs to the field of traditional Chinese medicine composition preparation component detection. The determining method of the present invention has characteristics of short period, good reproducibility and high sensitivity.

The invention discloses a traditional Chinese medicine preparation lumbus-strengthening kidney-tonifying pill detection method, according to the method, rehmannia glutinosa, yam, tuckahoe, schisandra, chrysanthemum and astragalus in a lumbus-strengthening kidney-tonifying pill can be microscopically identified, a radix angelicae sinensis referenee crude herb, ginsenoside Rg1, ginsenoside Re, ginsenoside Rb1, dipsacus asper saponin VI, astragaloside and deoxyschizandrin are used as reference substances, whether the lumbus-strengthening kidney-tonifying pill contains the radix angelicae sinensis ,ginseng, dipsacus asper, astragalus and schisandra can be identified by thin-layer chromatography; the dipsacus asper saponin VI content in the lumbus-strengthening kidney-tonifying pill preparation can be detected by HPLC, according to the detection method, the quantitative index is that the dipsacus asper saponin VI (C47H76O18) content in every 1g of the traditional Chinese medicine preparation lumbus-strengthening kidney-tonifying pill may not be less than 0.60mg, the controllability of quality standards of the traditional Chinese medicine preparation lumbus-strengthening kidney-tonifying pill can be improved to further ensure the product intrinsic quality and effect, so that the quality standard is more perfect, and the drug quality control level is improved.

The invention relates to a novel use of ginsenoside Rg1, especially the use in preventing or treating male sexual dysfunction such as ejection dysfunction.

The invention discloses a quality detection method of a ginseng basis-consolidating oral solution with the functions of nourishing yin and qi and consolidating basis. According to the quality detection method, the preparations of ginseng, dogwood, cortex moutan and rhizoma alismatis are distinguished with thin layer chromatography, and meanwhile the contents of ginsenosides Rg1 and Re of the ginseng, the content of paeonol of the cortex moutan, the contents of morroniside and loganin of the dogwood in the preparations are measured by adopting HPLC (high performance liquid chromatography). The quality detection method disclosed by the invention is stable, reliable, high in specificity and good in repeatability; content determination is carried out by selecting monarch drugs such as ginseng and cortex moutan containing volatile constituents in the prescription, so that the quality of the ginseng basis-consolidating oral solution can be comprehensively and effectively controlled, the stabilization for product quality is facilitated, the safety and effectiveness of clinical medication are guaranteed, and requirements of medical treatment and market are preferably met.

The invention relates to a preparation process for panaxoside monomer comprising the steps of, (1) dissolving total notoginseng saponin with alcohol, (2) passing through pretreated big hole resin columns, washing panaxatriol saponin with alcohol, rinsing the resin columns, (3) reclaiming alcohol through decompression, spray drying, obtaining panaxadiol saponin, (4) adsorbing on chromatographic silica gel, drying, (5) proceeding low pressure chromatography, (6) reclaiming solvent, vacuum drying to obtain the panaxoside Rg1 crude product, (7) proceeding step 4, 5 and 6 to obtain refined Rg1.

The invention relates to a pharmaceutical composition and a preparation method thereof. The pharmaceutical composition contains ginsenoside Rg1, ginsenoside Rb1 and ginsenoside Re, wherein the weight ratio of ginsenoside Rg1: ginsenoside Rb1: ginsenoside Re is 1:0.7:1.2. The composition provided by the invention has notable effects and high safety, can alleviate apoplexy symptoms, obviously shortens the course of disease, improves depression of patients with apoplexy sequelae, and the like.

The invention provides a pharmaceutical composition for invigorating qi and strengthening spleen. The pharmaceutical composition is a ginseng spleen-strengthening tablet which is prepared from the following materials such as 20-30g of ginseng, 45-55g of white atractylodes rhizome, 20-30g of liquorice, 70-80g of Chinese yam, 45-55g of lotus seed, 45-55g of white hyacinth bean, 15-25g of elecampane, 20-30g of alpinia katsumadai, 45-55g of pericarpium citri reticulatae, 45-55g of pericarpium citri reticulatae viride, 45-55g of maticated leaven, 45-55g of rice sprout, 45-55g of hawthorn, 45-55g of gorgon fruit, 95-105g of semen coicis, 45-55g of angelica sinensis, and 20-30g of fructus aurantii. The ginseng spleen-strengthening tablet is high in content of effective ingredients; especially, the content of saponin ingredients such as ginsenosides Rg1 and Re is higher than that in the prior art; and the pharmaceutical composition is better in treatment effect on the symptoms such as eating less and loose stool, vomiting or diarrhea, abdominal fullness and distention, limb weakness and sallow complexion caused by dampness stagnancy due to spleen deficiency.